Out of the 11 biotech companies entering the public market in the last year, eight have been from Washington state.
Just this summer, three companies, Absci, Icosavax and Eliem Therapeutics announced their IPO, bringing the grand total of money raised by Washington biotech companies over the last year to more than $2B.
“While a few Washington companies may have taken advantage of a wide-open IPO window to come out earlier than expected, I believe much of what we are witnessing reflects the maturation of our local industry,” said Dr. Leslie Alexandre, CEO of Life Science Washington.